Galectoincis A Clinical Stage Biotechnology Company Based In Copenhagendenmarkfounded In 2011 By Experts In Galectin Biologythe Company Is Publicly Traded On The Nasdaq Under The Ticker Symbol Gltogalecto Is Dedicated To Developing Innovative Treatments For Fibrotic Diseasescancerand Inflammationwith A Mission To Enhance The Quality Of Life For Patients Through Effective And Well Tolerated Therapies The Company Is Advancing Several Key Product Candidatesincluding Gb2064A Galectin 3 Inhibitor In Phase 2 Trials For Idiopathic Pulmonary Fibrosisand Gb0139Which Targets Galectin Proteins For Advanced Solid Tumorsother Candidates Include Gb1211An Oral Small Molecule For Various Oncology And Liver Disease Indicationsand Brm 1420A Dual Inhibitor For Acute Myeloid Leukemiagalecto Is Committed To Optimizing Its Resources For Ongoing Research And Development In These Therapeutic Areas
